Targeting the genetic and immunological drivers of cancer

Corporate Presentation
September 2019
Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, are "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” “pro forma,” or “anticipates,” or other similar words (including their use in the negative), or by discussions of future matters such as the development of current or future product candidates, timing of potential development activities and milestones, business plans and strategies, possible changes in legislation and other statements that are not historical. Forward-looking statements are based on current expectations of management and on what management believes to be reasonable assumptions based on information currently available to them, and are subject to risks and uncertainties. Such risks and uncertainties may cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation potential delays in development timelines, negative clinical trial results, reliance on third parties for development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks detailed in Mirati’s recent filings on Forms 10-K and 10-Q with the U.S. Securities and Exchange Commission. Except as required by law, Mirati undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Safe Harbor Statement
Mirati Therapeutics
Answering Cancer’s Challenges with a Targeted Approach

Who We Are:
- A Team of Knowledgeable and Experienced Oncology Drug Developers with a Track Record of Success in Rapidly Developing Multiple Therapies from Preclinical Development to the Market
- Applying Proven Approaches to the Development of Sitravatinib and MRTX849

Where We Are Focused:
- Addressing Areas of Unmet Need for Large Patient Populations
  - Treating cancer progression after checkpoint inhibitor therapy
  - Targeting KRAS mutations across multiple tumor types
- Utilizing our Knowledge to Expedite Development
  - From Identifying Lead to IND for MRTX849 in 9 months
### Mirati’s Development Pipeline Has Multiple Near-Term Milestones

<table>
<thead>
<tr>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase 1/1b</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Next Milestone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSCLC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Interim Analysis Q4 2020</strong>&lt;br&gt;<strong>Final Analysis Q4 2021</strong></td>
</tr>
<tr>
<td><strong>Bladder</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Clinical Data Update Q4 2019</strong></td>
</tr>
<tr>
<td>MOA Trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Mechanism of Action Clinical Data Q4 2019</strong></td>
</tr>
<tr>
<td><strong>Immuno-oncology</strong>&lt;br&gt;Sitravatinib + Nivolumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Early Proof of Concept Clinical Data Q4 2019</strong></td>
</tr>
<tr>
<td><strong>NSCLC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Clinical Data Update Q4 2019</strong></td>
</tr>
<tr>
<td><strong>Melanoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Clinical Data Update Q4 2019</strong></td>
</tr>
<tr>
<td><strong>CBL mutations</strong>&lt;br&gt;Targeted Single Agent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Clinical Candidate Selection 2019</strong></td>
</tr>
<tr>
<td><strong>MRTX849</strong>&lt;br&gt;KRAS G12C Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Clinical Data Update Q4 2019</strong></td>
</tr>
<tr>
<td><strong>CRC</strong>&lt;br&gt;KRAS G12D Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Clinical Candidate Selection 2019</strong></td>
</tr>
</tbody>
</table>

NSCLC = non-small cell lung cancer; CRC = colorectal cancer; RCC = renal cell cancer; HCC = hepatocellular cancer; IND = Investigational New Drug application; Tislelizumab (BeiGene’s anti-PD-1)

MOA = Mechanism of Action
Immuno-Oncology Combinations

Sitravatinib + Checkpoint Inhibitors
Sitravatinib in the Tumor Microenvironment Aims to Restore Immune Responses Through Inhibition of Immunosuppressive Signaling

**Tyro, Axl, Mer**
- Macrophages shift to Type 1 resulting in production of immune stimulating cytokines
- Enhances innate and adaptive immune response

**VEGFR2, KIT + Tyro, Axl, Mer**
- Increase: Dendritic cell dependent antigen presentation
- NK cell response
- T cell trafficking

**VEGFR2 & KIT**
- Reduction in Tregs and MDSCs
- Enhance CD8+ T-cell response

**Pre-Treatment**
- Immuno-suppressive

**Post-Treatment**
- Immuno-responsive

---

Garton et al., Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression. Mol Cancer Ther, 2017, 16(4)
Currently Enrolling Phase 3 Program in 2nd Line NSCLC
Sitravatinib + Nivolumab Randomized Phase 3 Trial Design

Two Opportunities for Approval in 2nd Line NSCLC:
- Interim Analysis: ORR, for Accelerated Approval (Q4’20)
- Primary Analysis: OS, for Full Approval (Q4’21)

Key Inclusion/Exclusion Criteria:
- Advanced, Non-Squamous NSCLC
- Progression on or following first line combination of PD-(L)1 inhibitor plus chemotherapy
- Excludes patients with known driver mutations

Endpoints:
- Interim: ORR (for potential Subpart H accelerated approval)
- Primary: OS (for potential full approval)
- Secondary: PFS, duration of response, safety, tolerability

Projected Phase 3 Timing:
- Study Initiation: Currently Enrolling
- Interim ORR Analysis: Q4 2020
- Primary OS Analysis: Q4 2021

ORR = Overall Response Rate; DOR = Duration of Response; OS = Overall Survival; PFS = Progression-Free Survival; NSCLC = non-small cell lung cancer
2nd Line NSCLC Represents a Significant Market Opportunity for Sitravatinib in Checkpoint Refractory Patients

Keytruda + Chemo 1st Line Has Created an Opportunity in 2nd Line

- **No/Low PD-L1**
  - 1L: Keytruda + Chemo
  - 2L: Checkpoint Refractory (Docetaxel Standard of Care)
  - 3L: Docetaxel
- **High PD-L1**
  - 1L: Keytruda

2017 NSCLC Market - US Sales

- **1st Line = $4.4B**
- **2nd Line = $2.8B**

Sources: EvaluatePharma, CancerMPact Patient Metrics and Kantar Health analysis
## Docetaxel: An Efficacy Comparator Used in Prior 2nd Line NSCLC Trials

### Advanced NSCLC

#### 2nd Line or Subsequent Therapy

<table>
<thead>
<tr>
<th>Trial</th>
<th>Compound</th>
<th>Pts</th>
<th>ORR, %</th>
<th>DOR, Mo.</th>
<th>PFS, Mo. (Range)</th>
<th>SD, %</th>
<th>CBR, % (CR+PR+SD)</th>
<th>OS, Mo. (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CheckMate 057(^1)</td>
<td>nivolumab</td>
<td>n=292</td>
<td>19%</td>
<td>17.2</td>
<td>2.3 (2.2-3.3)</td>
<td>25%</td>
<td>44%</td>
<td>12.2 (9.7-15.0)</td>
</tr>
<tr>
<td></td>
<td>docetaxel</td>
<td>n=290</td>
<td>12%</td>
<td>5.6</td>
<td>4.2 (3.5-4.9)</td>
<td>42%</td>
<td>54%</td>
<td>9.4 (8.1-10.7)</td>
</tr>
<tr>
<td>OAK(^2)</td>
<td>atezolizumab</td>
<td>n=425</td>
<td>14%</td>
<td>16.3</td>
<td>2.8 (2.6-3.0)</td>
<td>35%</td>
<td>49%</td>
<td>13.8 (11.8-15.7)</td>
</tr>
<tr>
<td></td>
<td>docetaxel</td>
<td>n=425</td>
<td>13%</td>
<td>6.2</td>
<td>4.0 (3.3-4.2)</td>
<td>42%</td>
<td>55%</td>
<td>9.6 (8.6-11.2)</td>
</tr>
<tr>
<td>KEYNOTE 010(^3)</td>
<td>pembrolizumab</td>
<td>n=345</td>
<td>18%</td>
<td>Not yet reported</td>
<td>3.9 (3.1-4.1)</td>
<td>10.4 (9.4-11.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>docetaxel</td>
<td>n=343</td>
<td>9%</td>
<td>6.1</td>
<td>4.0 (3.1-4.2)</td>
<td></td>
<td></td>
<td>8.5 (7.5-9.8)</td>
</tr>
<tr>
<td>MRTX-500(^4)</td>
<td>sitravatinib + nivolumab</td>
<td>n=56</td>
<td>20%</td>
<td>9.2*</td>
<td>6.8*</td>
<td>55%</td>
<td>75%</td>
<td>15.1*</td>
</tr>
</tbody>
</table>

Data presented is from separate studies and does not reflect results that might have been obtained from head-to-head studies. Results from Mirati’s planned Phase 3 trial comparing sitravatinib + nivolumab to docetaxel may differ materially from prior studies presented.

**Notes:**
- ORR = Overall Response Rate
- DOR = Duration of Response
- CBR = Clinical Benefit Rate (CR + PR + SD>14 weeks)
- SoC = Standard of Care
- CPI = Checkpoint Inhibitor Therapy
- * Preliminary Kaplan-Meier Estimate

---

4. Mirati ESMO 2018 Congress
Neo-Adjuvant Studies in RCC and HNSCC Present Near-Term Indication Expansion Opportunities for Sitravatinib

Presurgical Settings with Accessible Tumors

- Tissue biopsies following treatment with Sitravatinib alone and in combination
- Pharmacodynamic data from Tumor Micro Environment
- Evaluate clinical activity in neo-adjuvant setting

Timing

- Studies initiated in H2 2018
- Initial data planned for Q4 2019

**Study 1:** Renal Cell Carcinoma  
MD Anderson Cancer Center

**Study 2:** Head and Neck Cancer  
Princess Margaret – Toronto

**Neo-Adjuvant MOA Studies**

Clinical Trial Design

- **Segment 1**  
  Sitravatinib (2 weeks)  
  Tissue Biopsy

- **Segment 2**  
  Sitravatinib + nivolumab (2-4 weeks)  
  Tissue Biopsy

- **Surgery**

- **Tumor Resection**

RCC = renal cell cancer; HNSCC = head and neck squamous cell carcinoma
## Sitravatinib Has Opportunity for Broad Indication Expansion Across Multiple Tumor Types

### NSCLC
- **Build on clinical benefit demonstrated in NSCLC Phase 2 trial (MRTX-500)**
- **Expand clinical data with another checkpoint inhibitor (tislelizumab) and in the front-line setting**

### HCC and RCC
- **Pursue indications with strong clinical rationale for sitravatinib**

### Additional Indications
- **Expand to additional indications with opportunity to extend treatment options**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Phase 1/1b</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSCLC</strong></td>
<td>2nd line NSCLC checkpoint refractory <em>sitravatinib</em> + <em>nivolumab</em> vs. <em>docetaxel</em></td>
<td>2nd/3rd line NSCLC checkpoint refractory <em>sitravatinib</em> + <em>tislelizumab</em></td>
<td>1st line NSCLC PD-L1 High <em>sitravatinib</em> + <em>tislelizumab</em></td>
<td>Currently Enrolling</td>
</tr>
<tr>
<td>BeiGene</td>
<td></td>
<td></td>
<td>BeiGene</td>
<td></td>
</tr>
<tr>
<td><strong>HCC and RCC</strong></td>
<td>1st line HCC checkpoint naïve <em>sitravatinib</em> + <em>tislelizumab</em>; Sitravatinib alone</td>
<td>1st/2nd line RCC checkpoint naïve &amp; refractory <em>sitravatinib</em> + <em>tislelizumab</em></td>
<td></td>
<td>POC Data H2 2019</td>
</tr>
<tr>
<td>BeiGene</td>
<td></td>
<td></td>
<td>BeiGene</td>
<td></td>
</tr>
<tr>
<td><strong>Additional Indications</strong></td>
<td>2nd/3rd line Bladder checkpoint refractory <em>sitravatinib</em> + <em>nivolumab</em></td>
<td>RCC and HNSCC (pre-surgical) <em>sitravatinib</em> + <em>nivolumab</em></td>
<td>Ovarian cancer following platinum <em>sitravatinib</em> + <em>nivolumab</em></td>
<td>POC Data Q4 2019</td>
</tr>
<tr>
<td>BeiGene</td>
<td></td>
<td></td>
<td>BeiGene</td>
<td></td>
</tr>
<tr>
<td><strong>Additional Indications</strong></td>
<td>2nd/3rd line Gastric following chemotherapy <em>sitravatinib</em> + <em>tislelizumab</em></td>
<td></td>
<td></td>
<td>POC Data H2 2019</td>
</tr>
<tr>
<td>BeiGene</td>
<td></td>
<td></td>
<td>BeiGene</td>
<td></td>
</tr>
</tbody>
</table>
Sitravatinib Summary: Multiple Opportunities for I/O Combinations Across A Broad Range of Tumors

Positive Interim Phase 2 Efficacy Data in Checkpoint Refractory NSCLC\(^1\) (n=56)

75% 42/56 demonstrated Clinical Benefit \(^{(2)}\)

20% 11/56 achieved a Confirmed Partial or Complete Response

Preliminary Kaplan-Meier estimates \(^{(3)}\)

- Median DoR: 9.2 months
- Median PFS: 6.8 months
- Median OS: 15.1 months

Registration Path for 2\(^{nd}\) Line NSCLC: Phase 3 Randomized Trial Initiated in Q2 2019

- Sitravatinib + nivolumab vs. docetaxel in 2\(^{nd}\) line checkpoint refractory NSCLC
- Interim Analysis (ORR) for accelerated approval expected by year end 2020
- Primary Analysis (OS) for full approval by year end 2021

Phase 2 Clinical Trials in Other Indications

- Checkpoint Refractory Bladder Cancer: Initial Phase 2 data expected in Q4 2019
- Neo-adjuvant/Mechanism of Action Studies in RCC and HNSCC: Initial data expected in Q4 2019
- BeiGene Phase 2 Trials: Initial Phase 2 proof of concept data in NSCLC, HCC, RCC, Ovarian and Gastric expected in H2 2019 / H1 2020

---

1. Data presented at ESMO 2018 Congress; Data cut-off: 27-Aug-2018; Response data per investigator assessment, response confirmations updated after data cut-off.
2. Clinical Benefit defined as Stable Disease (SD), Partial Response (PR) or Complete Response (CR)
3. DoR = Duration of Response; PFS = Progression Free Survival; OS = Overall Survival
Targeted Oncology

Sitravatinib Single Agent: CBL Loss of Function Mutations
Sitravatinib Has a Unique Opportunity to Address CBL Loss-of-Function Mutations in Cancer

Loss-of-Function Mutations in CBL Result in Increased Target RTK Activation in Tumor Cells

**NORMAL**
- CBL down-regulates and turns off RTK signaling

**HYPERACTIVE**
- CBL loss of function increases RTK signaling

**Clinical update expected in H2 2019 to define single agent registration pathway**

**Single Agent Sitravatinib Program Focused on CBL in NSCLC and Melanoma**
- 1.5% of NSCLC and 3.5% of Melanoma
- Circulating tumor DNA assay (liquid biopsy) is now available to identify CBL loss of function mutations

**Initial Clinical Activity**
- 1/2 confirmed Partial Response in NSCLC
- 1/2 confirmed Partial Response in Melanoma

**Single Agent Sitravatinib Has Been Well Tolerated with Manageable Side Effects**

1. Presented at ESMO 2018 Congress; data cut-off 4-Sep-2018
Targeted Oncology

MRTX849: KRAS G12C Inhibitor
KRAS is the Most Frequently Mutated Gene in Human Cancer

KRAS Signaling

A key regulator of cell growth and survival

Abnormal KRAS Signaling

Mutated KRAS activity is uncontrolled
Mutant KRAS is an Oncogenic Tumor Driver That is Exclusive from Other Common Driver Mutations

KRAS mutations occur early and do not overlap with other driver mutations

Mutational Prevalence and Overlap in 1,357 Lung Adenocarcinomas¹

- HER2 (44)
- RET Fusion (20)
- KRAS G13 (37)
- KRAS G12 (346)
- MET (47)
- ROS1 (29)
- ALK Fusion (42)
- BRAF (65)
- EGFR L858R (109)
- EGFR Exon 19 Deletion (102)

Mutant KRAS signaling is required for tumor cell survival

Sensitivity of Cancer Cell Lines to shRNA Knockdown of KRAS²

2. McDonald et al, Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening, Cell 2017
KRAS G12C Mutations Occur Frequently in Multiple Tumor Types

KRAS G12C Mutation Frequency¹

- **NSCLC adenocarcinoma**: 14%
- **Colorectal**: 4%
- **Pancreatic**: 2%

Approx. US & EU Patients (²)  
- NSCLC: 44,400
- Colorectal: 19,600
- Pancreatic: 4,000

Total Addressable Pts: ~68,000


2. Mirati estimates based on epidemiology data reported in Globocan 2022 (accessed January 2019) and frequencies by mutation. Rounded to the nearest 100.
Addressing KRAS G12C+ Tumors is a Potential ~$7B Market Opportunity

Large Patient Population
US and EU Patients\(^1\)

```
US and EU Patients

<table>
<thead>
<tr>
<th>Condition</th>
<th>US Patients</th>
<th>EU Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRAS G12C</td>
<td>68,000</td>
<td></td>
</tr>
<tr>
<td>ALK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRK</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
```

Significant Commercial Potential
Projected US and EU Markets for KRAS G12C\(^2\)

```
~$7+ Billion Potential Market

<table>
<thead>
<tr>
<th>Condition</th>
<th>US Market</th>
<th>EU Market</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCLC</td>
<td>$4.9B</td>
<td></td>
</tr>
<tr>
<td>Colorectal</td>
<td>$2.2B</td>
<td></td>
</tr>
<tr>
<td>Pancreatic</td>
<td>$400M</td>
<td></td>
</tr>
</tbody>
</table>
```

1. Mirati estimates based on epidemiology data reported in Globocan 2022 (accessed January 2019) and frequencies by mutation; RET estimate does not include thyroid cancer
2. Mirati estimate, assuming revenue of $150,469 per US patient (net price of $16,719/mon and median duration of treatment of 9 months) and $90,281 per EU patient (40% discount to US). Duration of treatment modeled from clinical observations with MEK/RAF combination therapy in BRAF-mutated NSCLC.
Covalent KRAS G12C Inhibition is a Major Breakthrough in a Previously “Undruggable” Target

1. KRAS G12C has a cysteine present in its inactive form
2. Binding to the cysteine opens an adjacent Switch II pocket
3. Inhibitor covalently binds to the cysteine and the induced Switch II pocket
4. KRAS G12C is irreversibly locked in the inactive state

KRAS G12C Can Be Inhibited Covalently

Targeting KRAS
Historically “Undruggable”

Shallow Binding Pocket

GTP pocket

Picomolar Affinity for GTP

KRAS tumor cell death

MRTX849: KRAS G12C Inhibitor
MRTX849 is a Potent and Selective KRAS G12C Inhibitor

Potent

Antiproliferation IC50s
MRTX849, 3D format

Selective

Cysteine Selectivity in H358 Cells
MRTX849 (10 µM)

5,700 other cysteine peptides

Highly selective for KRAS G12C over other cysteines

KRAS G12C →
# MRTX849: Preclinical Attributes Have Potential to be Best-in-Class

<table>
<thead>
<tr>
<th>Attribute</th>
<th>Preclinical Attribute</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potency</td>
<td>Low nM potency across multiple cellular models of KRAS G12C</td>
</tr>
<tr>
<td>Selectivity</td>
<td>1,000+ fold selective for KRAS G12C vs. KRAS(^{WT}) and other protein cysteines</td>
</tr>
<tr>
<td>Oral Bioavailability</td>
<td>Preclinical projection of &gt;50% human bioavailability</td>
</tr>
<tr>
<td>Half Life</td>
<td>Preclinical projection of &gt;20 hour human half life</td>
</tr>
<tr>
<td>Therapeutic Index</td>
<td>Preclinical projection of &gt;10 fold safety margin</td>
</tr>
<tr>
<td>Volume of Distribution</td>
<td>Projected human volume of distribution exceeds 10 L/Kg</td>
</tr>
<tr>
<td>Extensive Tissue Distribution</td>
<td></td>
</tr>
</tbody>
</table>
MRTX849 Has Shown Promising *In Vivo* Antitumor Activity in CDX and PDX Models as a Single Agent

*Tumors did not recur at 100mg/kg despite cessation of treatment, indicating durable and complete responses*
Currently Enrolling Phase 1/2 Clinical Trial of MRTX849

Phase 1/2 Trial Design: Single Agent

**Phase 1: ACCELERATED DOSE ESCALATION**
- 150mg QD
- Dose Level 2
- Dose Level 3
- Dose Level 4

**Intra-Patient Dose Escalation**

**Phase 2: SINGLE AGENT EXPANSION COHORTS**
- NSCLC Cohort
- CRC Cohort
- “Basket” Cohort
- Other Tumors

**Potential Registration Path:**
- Single Arm Accelerated Approval
  - Objective Response Rate

**Phase 1 Initiated in January 2019**
- Only enrolling patients with G12C+ tumors
- Single patient cohorts with intra-patient dose escalation; may expand at any dose level
- 100% dose escalations, continuing up to the MTD
- Objective: Identify Recommended Phase 2 Dose (RP2D)

**Phase 2 Expansions Expected in H2 2019**
- RP2D cohorts will be expanded, by tumor type
- Potential for single arm accelerated approval based upon ORR
- “Basket” cohort may provide support for tumor agnostic approval
**In-Vivo Activity Suggests a Synergistic Effect of Combining MRTX849 with a PD-1 Inhibitor**

- KRAS G12C NSCLC tumors are primed for checkpoint inhibitor therapy with high levels of TMB and PD-L1 expression.
- MRTX849 treatment stimulates anti-tumor immunity and recruits CD4+ & CD8+ T cells in KRAS G12C-mutant tumors.
- MRTX849 combined with a PD-1 inhibitor may provide another path to first line treatment.

---

1. Preliminary results from MRTX849 testing in CT26 Clone E3 G12C syngeneic mouse model.
In-Vivo Activity Also Suggests a Synergistic Effect of Combining MRTX849 with a SHP2 Inhibitor

MRTX849 and SHP2 Inhibitor

- MRTX849 inhibits KRAS G12C which suppresses MAPK/ERK signaling and tumor growth.
- ERK inhibition hyperactivates EGFR and SHP2 signaling as an adaptive response to KRAS inhibition.
- Combinations of MRTX849 with EGFR or SHP2 inhibitors combat upstream reactivation of the RAS pathway.

July 2019: Mirati announced a clinical collaboration with Novartis’ TNO155 (SHP2 inhibitor)
Planned Initiation of Combination Clinical Trials in H2 2019

- Combination trials will enroll in parallel with single agent trials
- Combinations will be evaluated in patients with KRAS G12C+ tumors
- Opportunities for further patient selection will be evaluated

Phase 2: SINGLE AGENT EXPANSION COHORTS (registrational)

Phase 1/2: COMBINATION TRIALS

MRTX849 combined with:
- PD-1 Inhibitor
- SHP2 Inhibitor
- Pan-EGFR TKI
- CDK 4/6 Inhibitor

Signal Finding Phase 1/2 Trials
Active Combinations will be Advanced to Pivotal Trials
MRTX849 Summary: A Potential Best-in-Class KRAS G12C Inhibitor

Preclinical Attributes of MRTX849

- **Potent:** 1-20 nM potency in cellular assays
- **Selective:** 1,000 fold selective for KRAS G12C mutations over KRAS\textsuperscript{wild type}
- **Highly active in vivo:** complete durable regressions in KRAS G12C CDX and PDX models
- **Orally bioavailable:** preclinical projection of >50% human bioavailability
- **Long half life:** preclinical projection of >20 hour human half life maintains full inhibition of KRAS G12C

Significant Commercial Potential

- **Large Patient Population:** KRAS G12C incidence is ~24,500 in the U.S. alone \(^{(1)}\)
- **Large Commercial Opportunity:** Patient population is 3X larger than the $1.8B ALK market \(^{(2)}\)

Near-Term Milestones

- **Single-Agent:** Current Phase 1/2 Clinical Trial ongoing, with possibility of expansion into registrational
  - *Phase 1/2 Data Update Planned in Q4 2019*
- **Combination:** Could increase response rate and durability in resistant patient populations. Planned initiation of combination trials expected in H2 2019

---

1. Mirati estimates based on epidemiology data reported in Globocan 2022 (accessed January 2019) and frequencies by mutation
2. ALK market: 2018 worldwide sales
Targeted Oncology

KRAS G12D Program
Mirati’s Next KRAS Program: A Direct Inhibitor of KRAS G12D

Prevalent in Tumors with High Unmet Need

KRAS G12D Mutational Frequencies¹

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>KRAS G12D Frequency</th>
<th>Total US/EU Pts (²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreatic</td>
<td>35%</td>
<td>68,500</td>
</tr>
<tr>
<td>Colorectal</td>
<td>12%</td>
<td>58,900</td>
</tr>
<tr>
<td>Endometrial</td>
<td>5%</td>
<td>45,000</td>
</tr>
<tr>
<td>NSCLC adenocarcinoma</td>
<td>5%</td>
<td>9,800</td>
</tr>
</tbody>
</table>

Large Patient Population

US and EU Patients²

KRAS G12D Inhibitor

2. Mirati estimates based on epidemiology data reported in Globocan 2022 (accessed January 2019) and frequencies by mutation; RET estimate does not include thyroid cancer. Rounded to the nearest 100
# Mirati Therapeutics Has Multiple Potential Value-Driving Catalysts in 2H 2019

<table>
<thead>
<tr>
<th>Initiating Phase 3 Registrational Trial in NSCLC</th>
<th>Sitravatinib + Nivolumab in Checkpoint Refractory NSCLC Phase 3 Trial Initiation</th>
<th>Currently Enrolling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extending Proof of Concept into Additional Indications</td>
<td>Sitravatinib + Nivolumab in Checkpoint Refractory Bladder Phase 2 Initial Proof of Concept Data</td>
<td>Q4 2019</td>
</tr>
<tr>
<td></td>
<td>Sitravatinib + Tislelizumab in NSCLC, RCC, Ovarian Phase 2 Initial Proof of Concept Data (BeiGene)</td>
<td>H2 2019</td>
</tr>
<tr>
<td>Neo-Adjuvant Studies</td>
<td>Sitravatinib + Nivolumab in Pre-Surgical RCC, HNSCC Mechanism of Action and Initial Clinical Neo-Adjuvant Data</td>
<td>Q4 2019</td>
</tr>
<tr>
<td>MRTX849 KRAS G12C Program</td>
<td>MRTX849 in KRAS G12C Tumors Phase 1/2 Early Proof of Concept Data</td>
<td>Q4 2019</td>
</tr>
<tr>
<td>Potential Best-in-Class KRAS G12C Inhibitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expanding KRAS Franchise</td>
<td>KRAS G12D Program Lead Candidate Identification</td>
<td>Q4 2019</td>
</tr>
</tbody>
</table>

NSCLC = non-small cell lung cancer; CRC = colorectal cancer; RCC = renal cell cancer; HCC = hepatocellular cancer; HNSCC = head and neck squamous cell carcinoma; Tislelizumab (BeiGene’s anti PD-1)
<table>
<thead>
<tr>
<th></th>
<th>MRTX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash (Q2 19)*</td>
<td>$485.5M</td>
</tr>
<tr>
<td>Shares Outstanding**</td>
<td>49.0M</td>
</tr>
</tbody>
</table>

* Reported cash and investments as of June 30, 2019.
** As of June 30, 2019, includes 38.6 million shares of common stock and pre-funded warrants to purchase a total of 10.4 million shares of common stock. The pre-funded warrants have a per share exercise price of $0.001.
Targeting the genetic and immunological drivers of cancer

Corporate Presentation
September 2019
Back-up Slides
Phase 2 Trial of Sitravatinib + Nivolumab in Checkpoint Refractory NSCLC

MRTX-500 Trial - Design

Key Inclusion Criteria:
- Advanced/metastatic NSCLC
- Documented radiographic progression on prior checkpoint inhibitor therapy

Key Exclusion Criteria:
- No intervening therapy following progression on checkpoint inhibitor therapy
- No significant immune-related AEs with prior checkpoint therapy
- Exclude patients with known driver mutations

Endpoints:
- Primary: ORR
- Secondary: Safety and tolerability, duration of response, PFS, OS

Sitravatinib: Dose 120mg daily
Nivolumab: Dose 3mg/kg every 2 weeks (full labeled dose)
Study cycles of 28 days, with disease assessment scans every 2 cycles
Phase 2 Trial of Sitravatinib + Nivolumab in Checkpoint Refractory NSCLC

MRTX-500 Trial – Initial Responses

- **BEST RESPONSE**
  - (Evaluable Patients, N=56)
  - 42/56 (75%) Clinical Benefit (SD+PR+CR)
  - 18/56 (32%) Tumor Regression >30%
  - 11/56 (20%) Confirmed CR/PR

- **DURATION OF TREATMENT**
  - (Evaluable Patients, N=56)
  - Preliminary Kaplan-Meier Estimate of Median Duration of Response: 9.2 months

Study cycles of 28 days, with disease assessment scans every 2 cycles